南方医科大学学报 ›› 2005, Vol. 25 ›› Issue (11): 1452-1453.

• • 上一篇    下一篇

早期尿激酶静脉溶栓治疗急性心肌梗死24例临床分析

植绍权   

  1. 广东省东莞市望牛墩医院, 广东, 东莞, 523200
  • 出版日期:2005-11-20 发布日期:2005-11-20
  • 基金资助:
    收稿日期:2005-5-21。
    作者简介:植绍权(1967-),本科,主治医师,电话:0769-8531398

Clinical analysis of early stage thrombolytic therapy with venous urokinase for acute myocardial infarction in 24 cases

ZHI Shao-quan   

  1. 广东省东莞市望牛墩医院, 广东, 东莞, 523200
  • Online:2005-11-20 Published:2005-11-20

摘要: 目的 观察早期尿激酶静脉溶栓治疗急性心肌梗死(AMI)的疗效。方法 回顾分析24例采用早期尿激酶溶栓治疗与18例采用常规治疗的AMI患者的临床资料,观察溶栓治疗患者的再通情况及溶栓后24h内T波倒置对判断冠脉再通的影响。结果 尿激酶治疗组和常规治疗组的冠脉再通率分别为62.5%和15.0%(P<0.05),发病至开始溶栓的时间越短,再通率越高。结论 早期尿激酶静脉溶栓治疗可提高AMI疗效,降低病死率,宜早期应用。

Abstract: Objective To observe the therapeutic effect of early stage thrombolytic therapy with venous urokinase for acute myocardial infarction (AMI). Method The clinic data of 24 patients treated with early stage thrombolytic therapy with venous urokinase and 18 conventional therapy were reviewed, and the repatency of the coronary artery and T-wave inversion within 24 h after the treatment were evaluated. Result The repatency rate of urokinase group and conventional therapy group was 62.5% and 15.0%, respectively, showing significant difference (P<0.05). Shorter delay of administration of thrombolytic therapy after infarction onset resulted in higher rate of repatency. Conclusion Early stage thrombolytic therapy with venous urokinase can improve the therapeutic effect and reduce the mortality rate of AMI, and is therefore recommended for clinical application.

中图分类号: